CEO at OriCiro
Seiji is an Unreasonable Fellow. Seiji has participated in 1 program, including Unreasonable Impact Asia Pacific 2019.
Seiji co-founded OriCiro Genomics in December 2018 and has served as the CEO ever since. Prior to founding OriCiro, he was the COO and Head of Corporate Strategy at AnGes, a gene therapy company based in Tokyo. During his 16-year tenure at the company, he played a leading role in obtaining the regulatory approval for the company’s lead product, which was the first approval of a gene therapy product in Japan. He also successfully concluded many licensing, co-development and investment agreements with biotech and pharma companies in the business and corporate development functions. He started his professional career as a journalist at NIKKEI, a leading economic newspaper in Japan. He provided science, technology, and business news and reported on biotechnology, medicine, energy, environment, innovation, and science policy. He received his MSc in Physics from Tohoku University, Japan, and a MSc in Science and Technology Policy from the University of Sussex, U.K.